Xencor | XNCR - Interest Expense On Debt


Xencor reported $4.7M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Alnylam Pharmaceuticals USD 69.29M 60.05M Mar/2026
Amgen USD 657M 4M Mar/2026
Arrowhead Research USD 22.5M 811K Dec/2025
AstraZeneca USD 484M 181M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 411M 21M Mar/2026
Cytokinetics USD 33.34M 3M Mar/2026
GlaxoSmithKline GBP 167M 21M Mar/2026
J&J USD 43M 25M Mar/2026
Karyopharm Therapeutics USD 12.62M 1.24M Dec/2025
MacroGenics USD 3.34M 2.54M Sep/2025
Merck USD 479M 67M Mar/2026
Novartis USD 343M 39M Mar/2026
Pfizer USD 671M 40M Mar/2026
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Roche Holding CHF 304M 7.5M Jun/2025
Xencor USD 4.7M 2.65M Mar/2026